The company’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor.
This technology identified a practical method for detecting multiple gastrointestinal cancers from a single noninvasive blood test.
Given the data presented in this abstract, researchers indicated that it is crucial that further research works toward eliminating these disparities.
The patients with BRAF V600E-mutant metastatic colorectal cancer whose disease had progressed after 1 or 2 prior regimens reported substantial improvements in quality of life over the current standard of care.
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.
Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.
Research shows that digital videos led to increased knowledge and interventions, but access for vulnerable populations must be improved.
The drug has demonstrated the ability to reduce neutropenia induced by chemotherapy without affecting bone marrow or blood-G-CSF levels.
In this study, researchers looked at the adoption and use of bevacizumab in order to identify opportunities to increase use of high-value therapies.